Fresenius Medical Care (NYSE:FMS) announced today that its new growth strategy includes treating heart, lung and multi-organ failure.
Hamburg, Germany-based Fresenius’ strategy centers around three major areas: renal care, critical care solutions and complementary assets, according to a news release.
The company’s renal care continuum is to be bolstered by artificial intelligence and data analysis technologies for personalized care, while adding value-based care (transitioning from fee-for-service models to pay-for-performance models), kidney transplantation and new innovations with investments in startups and early-stage companies in the space.
Additionally, Fresenius will extend its critical care portfolio to other extracorporeal intensive care therapy areas, including treating heart, lung and multi-organ failure.
Finally, the company intends to leverage its existing network to create an additional basis for future growth, expanding its network of complementary assets through partnerships, investments and acquisitions.
With the new strategy, Fresenius announced a new medium-term outlook through 2025, expecting average increases annually in the mid-single-digit percentage range for revenue and the upper-single-digit percentage range for net income.
“The new strategy is our next logical step,” Fresenius Medical Care CEO Rice Powell said in the release. “It’s the next step up from our four core competencies, it’s a step up for our network – and it’s a step in our quest for even more valuable solutions for our patients as well as for payors and health care systems around the world.”
